EQL Pharma AB (OSTO:EQL) GF Score: 42/100 (As of Jul. 05, 2026) — Near Median


OSTO:EQL EQL Pharma AB OSTO:EQL
42 GF Score
Price kr23.85
! 4 Warning Signs
View Full Analysis

What is EQL Pharma AB GF Score?

EQL Pharma AB OSTO:EQL +3.02% 42 GF Score is 42 as of Jul. 05, 2026, which is 2% above its 10-year median of 41.00. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review.

EQL Pharma AB has the GF Score of 42, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 9/10
3. Growth Rank : 8/10
4. GF Value Rank : 2/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes EQL Pharma AB might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

EQL Pharma AB  (OSTO:EQL) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

EQL Pharma AB GF Score Related Terms

OSTO:EQL vs ZTS, UTHR: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EQL Pharma AB GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's GF Score distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's GF Score falls into.


OSTO:EQL
42GF Score
EQL Pharma AB OSTO:EQL
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 42 mean?
EQL Pharma AB (OSTO:EQL) has a GF Score of 42 as of Jul. 05, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on EQL Pharma AB and its competitors. This is near median its historical median of 41.00. Over the past decade, EQL Pharma AB's GF Score has ranged from 35.00 to 60.00.
Is EQL Pharma AB's GF Score too high?
EQL Pharma AB's current GF Score of 42 is near median its 10-year median of 41.00. Over the past 10 years, this metric has ranged from a low of 35.00 to a high of 60.00. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's GF Score compare to ZTS and UTHR?
EQL Pharma AB's GF Score of 42 can be compared against companies in the Drug Manufacturers industry. Historically, EQL Pharma AB's own GF Score has ranged from 35.00 to 60.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on EQL Pharma AB and its competitors. EQL Pharma AB's current GF Score is 42, which is near median its own 10-year median of 41.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current GF Score of 42. The current GF Score is 42, which is near median its 10-year median of 41.00. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current GF Score is 42 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Other Exchanges 7JK:Germany
Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score

Get the complete analysis for OSTO:EQL

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.85
Price